{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:00:15Z","timestamp":1758970815538,"version":"3.37.3"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,12,12]],"date-time":"2015-12-12T00:00:00Z","timestamp":1449878400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s11239-015-1306-3","type":"journal-article","created":{"date-parts":[[2015,12,12]],"date-time":"2015-12-12T01:50:23Z","timestamp":1449885023000},"page":"254-260","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dual pathway therapy in acute coronary syndrome"],"prefix":"10.1007","volume":"42","author":[{"given":"Peter","family":"Stachon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"Ahrens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Bode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6290-3297","authenticated-orcid":false,"given":"Andreas","family":"Zirlik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,12]]},"reference":[{"issue":"3","key":"1306_CR1","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1161\/01.cir.0000441139.02102.80","volume":"129","author":"AS Go","year":"2014","unstructured":"Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ et al (2014) Heart disease and stroke statistics\u20132014 update: a report from the American Heart Association. Circulation 129(3):e28\u2013e292","journal-title":"Circulation"},{"issue":"2","key":"1306_CR2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM197907123010201","volume":"301","author":"AR Gruntzig","year":"1979","unstructured":"Gruntzig AR, Senning A, Siegenthaler WE (1979) Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 301(2):61\u201368","journal-title":"N Engl J Med"},{"issue":"8","key":"1306_CR3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa025142","volume":"349","author":"HR Andersen","year":"2003","unstructured":"Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P et al (2003) A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 349(8):733\u2013742","journal-title":"N Engl J Med"},{"issue":"4","key":"1306_CR4","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742cf6","volume":"127","author":"PT O\u2019Gara","year":"2013","unstructured":"O\u2019Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA et al (2013) 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation 127(4):e362\u2013e425","journal-title":"Circulation"},{"issue":"12","key":"1306_CR5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJM198703193161201","volume":"316","author":"U Sigwart","year":"1987","unstructured":"Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L (1987) Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 316(12):701\u2013706","journal-title":"N Engl J Med"},{"issue":"8","key":"1306_CR6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJM199408253310801","volume":"331","author":"PW Serruys","year":"1994","unstructured":"Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G et al (1994) A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 331(8):489\u2013495","journal-title":"N Engl J Med"},{"issue":"8","key":"1306_CR7","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJM199408253310802","volume":"331","author":"DL Fischman","year":"1994","unstructured":"Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I et al (1994) A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 331(8):496\u2013501","journal-title":"N Engl J Med"},{"issue":"5","key":"1306_CR8","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1056\/NEJMra051091","volume":"354","author":"PW Serruys","year":"2006","unstructured":"Serruys PW, Kutryk MJ, Ong AT (2006) Coronary-artery stents. N Engl J Med 354(5):483\u2013495","journal-title":"N Engl J Med"},{"issue":"14","key":"1306_CR9","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJMoa035071","volume":"349","author":"JW Moses","year":"2003","unstructured":"Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O\u2019Shaughnessy C et al (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349(14):1315\u20131323","journal-title":"N Engl J Med"},{"issue":"4","key":"1306_CR10","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1136\/hrt.2004.059295","volume":"92","author":"T Rodriguez","year":"2006","unstructured":"Rodriguez T, Malvezzi M, Chatenoud L, Bosetti C, Levi F, Negri E et al (2006) Trends in mortality from coronary heart and cerebrovascular diseases in the Americas: 1970\u20132000. Heart 92(4):453\u2013460","journal-title":"Heart"},{"issue":"11","key":"1306_CR11","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045\u20131057","journal-title":"N Engl J Med"},{"issue":"11","key":"1306_CR12","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.2515","volume":"17","author":"SP Jackson","year":"2011","unstructured":"Jackson SP (2011) Arterial thrombosis\u2013insidious, unpredictable and deadly. Nat Med 17(11):1423\u20131436","journal-title":"Nat Med"},{"issue":"6921","key":"1306_CR13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","volume":"308","author":"Antiplatelet Trialists\u2019 Collaboration","year":"1994","unstructured":"Antiplatelet Trialists\u2019 Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy\u2013I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308(6921):81\u2013106","journal-title":"BMJ"},{"issue":"9302","key":"1306_CR14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","volume":"359","author":"E Boersma","year":"2002","unstructured":"Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de Werf F et al (2002) Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359(9302):189\u2013198","journal-title":"Lancet"},{"issue":"21","key":"1306_CR15","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1056\/NEJM199805213382103","volume":"338","author":"Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators","year":"1998","unstructured":"Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators (1998) A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 338(21):1498\u20131505","journal-title":"N Engl J Med"},{"issue":"7","key":"1306_CR16","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","volume":"339","author":"The PURSUIT Trial Investigators","year":"1998","unstructured":"The PURSUIT Trial Investigators (1998) Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein iib\/iiia in unstable angina: receptor suppression using integrilin therapy. N Engl J Med 339(7):436\u2013443","journal-title":"N Engl J Med"},{"issue":"9272","key":"1306_CR17","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(00)05060-1","volume":"357","author":"ML Simoons","year":"2001","unstructured":"Simoons ML (2001) Investigators GI-A. Effect of glycoprotein IIb\/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 357(9272):1915\u20131924","journal-title":"Lancet"},{"issue":"2","key":"1306_CR18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.CIR.103.2.201","volume":"103","author":"DP Chew","year":"2001","unstructured":"Chew DP, Bhatt DL, Sapp S, Topol EJ (2001) Increased mortality with oral platelet glycoprotein IIb\/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 103(2):201\u2013206","journal-title":"Circulation"},{"issue":"17","key":"1306_CR19","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","volume":"334","author":"A Schomig","year":"1996","unstructured":"Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M et al (1996) A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334(17):1084\u20131089","journal-title":"N Engl J Med"},{"issue":"23","key":"1306_CR20","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","volume":"339","author":"MB Leon","year":"1998","unstructured":"Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK et al (1998) A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339(23):1665\u20131671","journal-title":"N Engl J Med"},{"issue":"9133","key":"1306_CR21","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(05)60079-7","volume":"352","author":"CL Bennett","year":"1998","unstructured":"Bennett CL, Kiss JE, Weinberg PD, Pinevich AJ, Green D, Kwaan HC et al (1998) Thrombotic thrombocytopenic purpura after stenting and ticlopidine. Lancet 352(9133):1036\u20131037","journal-title":"Lancet"},{"issue":"7","key":"1306_CR22","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S Yusuf","year":"2001","unstructured":"Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345(7):494\u2013502","journal-title":"N Engl J Med"},{"issue":"11","key":"1306_CR23","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMe0906549","volume":"361","author":"A Schomig","year":"2009","unstructured":"Schomig A (2009) Ticagrelor\u2013is there need for a new player in the antiplatelet-therapy field? N Engl J Med 361(11):1108\u20131111","journal-title":"N Engl J Med"},{"issue":"20","key":"1306_CR24","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357(20):2001\u20132015","journal-title":"N Engl J Med"},{"issue":"9892","key":"1306_CR25","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(13)61451-8","volume":"382","author":"SD Wiviott","year":"2013","unstructured":"Wiviott SD, White HD, Ohman EM, Fox KA, Armstrong PW, Prabhakaran D et al (2013) Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet 382(9892):605\u2013613","journal-title":"Lancet"},{"issue":"24","key":"1306_CR26","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","volume":"361","author":"DL Bhatt","year":"2009","unstructured":"Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G et al (2009) Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 361(24):2330\u20132341","journal-title":"N Engl J Med"},{"issue":"24","key":"1306_CR27","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","volume":"361","author":"RA Harrington","year":"2009","unstructured":"Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM et al (2009) Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 361(24):2318\u20132329","journal-title":"N Engl J Med"},{"issue":"14","key":"1306_CR28","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","volume":"368","author":"DL Bhatt","year":"2013","unstructured":"Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW et al (2013) Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 368(14):1303\u20131313","journal-title":"N Engl J Med"},{"issue":"3","key":"1306_CR29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2011.2002","volume":"307","author":"DJ Angiolillo","year":"2012","unstructured":"Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ et al (2012) Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 307(3):265\u2013274","journal-title":"JAMA"},{"issue":"15","key":"1306_CR30","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","volume":"366","author":"DA Morrow","year":"2012","unstructured":"Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP et al (2012) Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366(15):1404\u20131413","journal-title":"N Engl J Med"},{"key":"1306_CR31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-3-642-29423-5_5","volume":"210","author":"C Schulz","year":"2012","unstructured":"Schulz C, Massberg S (2012) Platelets in atherosclerosis and thrombosis. Handb Exp Pharmacol 210:111\u2013133","journal-title":"Handb Exp Pharmacol"},{"issue":"3","key":"1306_CR32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1067\/mhj.2000.108823","volume":"140","author":"A Bayes-Genis","year":"2000","unstructured":"Bayes-Genis A, Mateo J, Santalo M, Oliver A, Guindo J, Badimon L et al (2000) D-Dimer is an early diagnostic marker of coronary ischemia in patients with chest pain. Am Heart J 140(3):379\u2013384","journal-title":"Am Heart J"},{"issue":"1","key":"1306_CR33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.CIR.90.1.61","volume":"90","author":"PA Merlini","year":"1994","unstructured":"Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C et al (1994) Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 90(1):61\u201368","journal-title":"Circulation"},{"issue":"9219","key":"1306_CR34","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0140-6736(00)02324-2","volume":"355","author":"JW Eikelboom","year":"2000","unstructured":"Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S (2000) Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 355(9219):1936\u20131942","journal-title":"Lancet"},{"issue":"3","key":"1306_CR35","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/ncpcardio0135","volume":"2","author":"RP Giugliano","year":"2005","unstructured":"Giugliano RP, Braunwald E (2005) 2004 ACC\/AHA guideline for the management of patients with STEMI: the implications for clinicians. Nat Clin Pract Cardiovasc Med 2(3):114\u2013115","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"13","key":"1306_CR36","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","volume":"347","author":"M Hurlen","year":"2002","unstructured":"Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H (2002) Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 347(13):969\u2013974","journal-title":"N Engl J Med"},{"issue":"9327","key":"1306_CR37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0140-6736(02)09409-6","volume":"360","author":"RF Es van","year":"2002","unstructured":"van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE, Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group (2002) Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 360(9327):109\u2013113","journal-title":"Lancet"},{"issue":"4","key":"1306_CR38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-143-4-200508160-00005","volume":"143","author":"MB Rothberg","year":"2005","unstructured":"Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR (2005) Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 143(4):241\u2013250","journal-title":"Ann Intern Med"},{"issue":"5","key":"1306_CR39","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/eurheartj\/ehi485","volume":"27","author":"F Andreotti","year":"2006","unstructured":"Andreotti F, Testa L, Biondi-Zoccai GG, Crea F (2006) Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 27(5):519\u2013526","journal-title":"Eur Heart J"},{"issue":"26","key":"1306_CR40","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","volume":"363","author":"E Investigators","year":"2010","unstructured":"Investigators E, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499\u20132510","journal-title":"N Engl J Med"},{"issue":"9","key":"1306_CR41","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","volume":"364","author":"SJ Connolly","year":"2011","unstructured":"Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S et al (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364(9):806\u2013817","journal-title":"N Engl J Med"},{"key":"1306_CR42","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ijcard.2015.03.369","volume":"191","author":"CH Chen","year":"2015","unstructured":"Chen CH, Chen MC, Gibbs H, Kwon SU, Lo S, On YK et al (2015) Antithrombotic treatment for stroke prevention in atrial fibrillation: the Asian agenda. Int J Cardiol 191:244\u2013253","journal-title":"Int J Cardiol"},{"issue":"6","key":"1306_CR43","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2014-03-563577","volume":"124","author":"J Beyer-Westendorf","year":"2014","unstructured":"Beyer-Westendorf J, Forster K, Pannach S, Ebertz F, Gelbricht V, Thieme C et al (2014) Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 124(6):955\u2013962","journal-title":"Blood"},{"issue":"2","key":"1306_CR44","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0002-9343(98)00198-3","volume":"105","author":"RJ Beyth","year":"1998","unstructured":"Beyth RJ, Quinn LM, Landefeld CS (1998) Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 105(2):91\u201399","journal-title":"Am J Med"},{"issue":"22","key":"1306_CR45","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/eurheartj\/eht049","volume":"34","author":"J Oldgren","year":"2013","unstructured":"Oldgren J, Wallentin L, Alexander JH, James S, Jonelid B, Steg G et al (2013) New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J 34(22):1670\u20131680","journal-title":"Eur Heart J"},{"issue":"9386","key":"1306_CR46","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","volume":"362","author":"L Wallentin","year":"2003","unstructured":"Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nystrom P et al (2003) Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 362(9386):789\u2013797","journal-title":"Lancet"},{"issue":"5","key":"1306_CR47","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2011.1666","volume":"172","author":"K Uchino","year":"2012","unstructured":"Uchino K, Hernandez AV (2012) Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 172(5):397\u2013402","journal-title":"Arch Intern Med"},{"issue":"3","key":"1306_CR48","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2796.2011.02354.x","volume":"270","author":"C Christersson","year":"2011","unstructured":"Christersson C, Oldgren J, Wallentin L, Siegbahn A (2011) Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction. J Intern Med 270(3):215\u2013223","journal-title":"J Intern Med"},{"issue":"9","key":"1306_CR49","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1161\/hq0901.095148","volume":"21","author":"S Bassus","year":"2001","unstructured":"Bassus S, Herkert O, Kronemann N, Gorlach A, Bremerich D, Kirchmaier CM et al (2001) Thrombin causes vascular endothelial growth factor expression in vascular smooth muscle cells: role of reactive oxygen species. Arterioscler Thromb Vasc Biol 21(9):1550\u20131555","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"1306_CR50","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","volume":"365","author":"JH Alexander","year":"2011","unstructured":"Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P et al (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365(8):699\u2013708","journal-title":"N Engl J Med"},{"issue":"1","key":"1306_CR51","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5482\/HAMO-13-09-0048","volume":"34","author":"I Ahrens","year":"2014","unstructured":"Ahrens I, Bode C, Zirlik A (2014) Anticoagulation during and after acute coronary syndrome. Hamostaseologie 34(1):72\u201377","journal-title":"Hamostaseologie"},{"issue":"9683","key":"1306_CR52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","volume":"374","author":"JL Mega","year":"2009","unstructured":"Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F et al (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374(9683):29\u201338","journal-title":"Lancet"},{"issue":"4","key":"1306_CR53","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jacc.2013.03.041","volume":"62","author":"CM Gibson","year":"2013","unstructured":"Gibson CM, Chakrabarti AK, Mega J, Bode C, Bassand JP, Verheugt FW et al (2013) Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am Coll Cardiol 62(4):286\u2013290","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1306_CR54","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C et al (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366(1):9\u201319","journal-title":"N Engl J Med"},{"issue":"8","key":"1306_CR55","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","volume":"114","author":"JW Eikelboom","year":"2006","unstructured":"Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114(8):774\u2013782","journal-title":"Circulation"},{"issue":"23","key":"1306_CR56","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"CW Hamm","year":"2011","unstructured":"Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H et al (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32(23):2999\u20133054","journal-title":"Eur Heart J"},{"issue":"9872","key":"1306_CR57","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","volume":"381","author":"WJ Dewilde","year":"2013","unstructured":"Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP et al (2013) Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381(9872):1107\u20131115","journal-title":"Lancet"},{"issue":"15","key":"1306_CR58","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","volume":"60","author":"BK Kim","year":"2012","unstructured":"Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG et al (2012) A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 60(15):1340\u20131348","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"1306_CR59","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","volume":"64","author":"A Colombo","year":"2014","unstructured":"Colombo A, Chieffo A, Frasheri A, Garbo R, Masotti-Centol M, Salvatella N et al (2014) Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol 64(20):2086\u20132097","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-015-1306-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-015-1306-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-015-1306-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T07:02:11Z","timestamp":1559372531000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-015-1306-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,12]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["1306"],"URL":"https:\/\/doi.org\/10.1007\/s11239-015-1306-3","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"type":"print","value":"0929-5305"},{"type":"electronic","value":"1573-742X"}],"subject":[],"published":{"date-parts":[[2015,12,12]]}}}